RSS-Feed abonnieren
DOI: 10.1055/s-2006-956289
© Georg Thieme Verlag KG Stuttgart · New York
Kurzwirksame Insulinanaloga - Kritische Bewertung metaanalytischer Betrachtungen
Short-acting insulin analogs - critical assessment of meta-analysesPublikationsverlauf
eingereicht: 5.7.2006
akzeptiert: 26.10.2006
Publikationsdatum:
30. November 2006 (online)

Zusammenfassung
Kurzwirksame Insulinanaloga werden seit fast 10 Jahren bei der Behandlung des Diabetes mellitus Typ 1 und 2 eingesetzt. Es gibt eine ausführliche potentielle wissenschaftliche und praktische Evidenz für deren potentielle Überlegenheit gegenüber Normalinsulin. Daher werden diese Insuline bereits von den meisten führenden Fachgesellschaften in ihren Leitlinien empfohlen. Im klinischen Alltag stellen sie eine wesentliche Komponente des therapeutischen Portfolios dar, die insbesondere bei selektivem Einsatz zu einer deutlichen Verbesserung der Insulintherapie führen kann. Andererseits muss insbesondere auch in Deutschland dem wachsenden ökonomischen Druck Rechnung getragen werden. Dennoch darf die Kritik vorgetragen werden, dass Metaanalysen zu diesem Thema, die im Auftrag von Versicherungsträgern oder Regierungsbehörden erstellt worden sind, der wissenschaftlichen und Versorgungsrealität nicht gerecht werden. Aktuelle Metaanalysen zu den kurzwirksamen Insulinanaloga schließen entscheidende Vorteile von Insulinanaloga aus Analysen aus und vergleichen sehr heterogene Gruppen. Es wird nicht differenziert zwischen unterschiedlichen Hypoglykämieprävalenzen bei unterschiedlichen HbA 1c-Werten sowie konventioneller und intensivierter Therapie. Zudem schließt man positive Daten und positive Major-Studien aus, während Zulassungsstudien oder Studien mit gänzlich differenter Fragestellung zitiert werden. Zu kritisieren ist häufig auch die kurze Studiendauer. Die International Diabetes Federation (IDF) hat daher das Cochrane-Review aus dem Jahr 2005 methodisch abgelehnt, und auch aus dem IQWiG-Gutachten lassen sich keine reliablen therapeutische Empfehlungen ableiten.
Summary
Short-acting insulin analogs have for nearly ten years been prescribed for type 1 and 2 diabetes mellitus. There is extensive scientific and practical evidence of their being better than normal insulin. For this reason these insulins have been recommended in the guidelines of most leading specialist societies. In everyday practice they are an important component of the therapeutic portfolio which can produce an improvement in insulin treatment, especially of selective cases. On the other hand, there is growing economic pressure, especially in Germany, affecting their use. However, it must be critically asserted that those meta-analyses on insulin analogs, which have been commissioned by insurance companies or governmental organisations, do not do justice to their advantage. Current meta-analyses of short-acting insulin analogs exclude decisive advantages of insulin analogs from their analyses and compare highly heterogeneous groups. They do not distinguish between differing incidences of hypoglycemia associated with different HbA1c values as well as between conventional and intensive treatment. Furthermore positive data and positive major studies are excluded, while approval studies or trials with completely different aims are cited. Short study duration is also often neglected. As a result, the International Diabetes Federation (IDF) has rejected the Cochrane Review for 2005 for methodological reasons. Also, no recommendations can be derived from the recommendations of of the Institut für Qualitätssicherung und Wirtschaftlichkeit in der Medizin (IQWiG: Institute for Quality Assurance and Cost Effectiveness in Medicine). After critical assessment of meta-analyses the IDF concluded in its guidelines that insulin analogs should generally be used.
Schlüsselwörter
kurzwirksame Insulinanaloga - Insulin Lispro - Insulin Aspart - Insulin Glulisin
Key words
Short-acting insulin analogs - insulin lispro - insulin aspart - insulin glulisin
Literatur
- 1
Altuntas Y, Ozen B, Ozturk B. et al .
Comparison of additional metformin or NPH insulin to mealtime insulin lispro therapy
with mealtime human insulin therapy in secondary OAD failure.
Diabetes Obes Metab.
2003;
5
371-378
MissingFormLabel
- 2
Anderson J H, Brunelle R L, Keohane P. et al .
Mealtime treatment with insulin analog improves postprandial hyperglycemia in patients
with non-insulin-dependent diabetes mellitus. Multcenter Insulin Lispro Study Group.
Arch Intern Med.
1997;
157
1249-1255
MissingFormLabel
- 3
Anderson J H, Brunelle R L, Koivisto V A, Trautmann V E, Vignati L, DiMarchi R. and the Insulin Lispro Study Group .
Improved mealtime treatment of diabetes mellitus using an insulin analogue.
Clin Ther.
1997;
19
62-72
MissingFormLabel
- 4
Bastyr E J, Yuang H, Brunelle R L, Vignati L, Cox D J, Kotsanos J G.
Factors associated with nocturnal hypoglycaemia among patients with type 2 diabetes
new to insulin therapy: experience with insulin lispro.
Diabetes Obes Metab.
2000;
2
39-46
MissingFormLabel
- 5
Boehm B O, Home P D, Behrend C, Kamp N M, Lindholm A.
Premixed insulin aspart 30 vs. Premixed human insulin 30/70 twice daily: a randomized
trial in type 1 and type 2 diabetic patients.
Diabet Med.
2002;
19
393-399
MissingFormLabel
- 6
Brunner G A, Hirschberger S, Sendlhofer G. et al .
Post-prandial administration of the insulin analogue insulin aspart in patients with
type 1 diabetes mellitus.
Diabet Med.
2000;
17
371-375
MissingFormLabel
- 7
Ciofetta M, Lalli C, Del Sindaco P. et al .
Contribution of postprandial versus interprandial blood glucose to HbA1c in type 1
diabetes on physiologic intensive therapy with lispro insulin at mealtime.
Diabetes Care.
1999;
22
795-800
MissingFormLabel
- 8 Clinical Study Report, HMR1964 - 3002. 26-week, multinational, multicenter, controlled
open, 1:1 randomized, parallel, clinical trial to assess noninferiority between HMR1964
and regular human insulin injected subcutaneously in subjects with type 2 diabetes
mellitus also using NPH insulin .
MissingFormLabel
- 9
Dailey G, Moses R G, Rosenstock J, Ways K.
Insulin Glulisine provides improved glycemic control in patients with type 2 diabetes.
Diabetes Care.
2004;
27
2363-2368
MissingFormLabel
- 10 EMEA. EPAR Insulin Lispro (Humalog) - Scientific discussion. http://www.emea.eu.int/humandocs/PDFs/EPAR/Humalog/060195en6.pdf Einsicht: 1.6.06 (Verfügbarkeit am 13.11.06 überprüft).
MissingFormLabel
- 11
Gale E AM.
A randomized, controlled trial comparing insulin lispro with human soluble insulin
in patients with type 1 diabetes on intensified insulin therapy.
Diabet Med.
2000;
17
209-214
MissingFormLabel
- 12
Hedman C A, Orre-Pettersson A C, Lindstrom T, Arnqvist H J.
Treatment with insulin lispro changes the insulin profile but does not affect the
plasma concentrations of IGF-I and IGFBP-1 in type 1 diabetes.
Clin Endocrinol.
2001;
55
107-112
MissingFormLabel
- 13
Herz M, Profozioc V, Arora V, Smircic-Duvnjak L, Kovacevic I, Boras J.
Effects of a mixed mixture of 25 % insulin lispro and 75 % NPL on plasma glucose during
and after moderate physical exercise in patients with type 2 diabetes.
Cur Med Res Opin.
2002;
18
188-193
MissingFormLabel
- 14
Herz M, Arora V, Campaigne B N, Scholtz H E, Potgieter M A, Mollentze W.
Humalog Mix25 improves 24-hour profiles compared with the human insulin mixture 30/70
in patients with type 2 diabetes mellitus.
S Afr Med J.
2003;
93
219-223
MissingFormLabel
- 15
Holleman F, Schmitt H, Rottiers R, Rees A, Symanowski S, Anderson J H.
Reduced frequency of severe hypoglycaemia and coma in well-controlled IDDM patients
treated with insulin lispro.
Diabetes Care.
1997;
20
1827-1832
MissingFormLabel
- 16 Institut für Qualitätssicherung und Wirtschaftlichkeit in der Medizin (IQWIG) .Kurzwirksame Insulinanaloga zur Behandlung des Diabetes mellitus Typ 2 - Abschlussbericht. Version 1.0 15.12.2005: www.iqwig.de
MissingFormLabel
- 17
Kurtzhals P, Schaffer L, Sorenson A.
Correlations of receptor binding and metabolic and mitogenic potencies of insulin
analogs designed for clinical use.
Diabetes.
2000;
49
999-1005
MissingFormLabel
- 18
Lalli C, Ciofetta M, Del Sindaco P. et al .
Long-term intensive treatment of type 1 diabetes with the short-acting insulin analog
lispro in variable combination with NPH insulin at mealtime.
Diabetes Care.
1999;
22
468-477
MissingFormLabel
- 19
Orre-Petersson A C, Lindstrom T, Bergmark V, Arnqvist H J.
The snack is critical for the blood glucose profile during treatment with regular
insulin preprandially.
J Intern Med.
1999;
245
41-45
MissingFormLabel
- 20
Paquot N, Roulin D, Schneiter P. et al .
Effects of regular insulin or insulin lispro on glucose metabolism after an oral glucose
load in patients with type 2 diabetes mellitus.
Diabetes Metab.
1998;
24
523-528
MissingFormLabel
- 21
Plank J, Siebenhofer A, Berghold A. et al .
Systematic review and meta-analysis of short-acting analogues in patients with diabetes
mellitus.
Arch Intern Med.
2005;
165
1337-1344
MissingFormLabel
- 22
Sackett D L, Rosenberg W M, Gray J A, Haynes R B, Richardson W S.
Evidence based medicine: what it is and what it isn’t.
BMJ.
1996;
312
71-72
MissingFormLabel
- 23
Scheen A J, Letiexhe M R, Lefebvre P J.
Minimal influence of the time interval between injection of regular insulin and food
intake on blood glucose control of type 1 diabetic patients on a basal-bolus insulin
scheme.
Diabetes Metab.
1999;
25
157-162
MissingFormLabel
- 24
Schernthaner G, Wein W, Shnawa N, Bates P C, Birkett M A.
Preprandial vs. postprandial insulin lispro - a comparative crossover trial in patients
with type 1 diabetes.
Diabet Med.
2004;
21
279-284
MissingFormLabel
- 25
Siebenhofer A, Plank J, Berghold A. et al .
Short acting analogues versus regular human insulin in patients with diabetes mellitus.
Cochrane Database Syst Rev.
2006;
4
CD003287
MissingFormLabel
- 26
Slieker L J, Brooke G S, DiMarchi R D. et al .
Modifications in the B10 and B26 - 30 regions of the B chain of human insulin alter
affinity for the human IGF-I receptor more than for the insulin receptor.
Diabetologia.
1997;
40
S54-S61
MissingFormLabel
Priv.-Doz. Dr. Thomas Kunt
Diabetesschwerpunktpraxis
Friedrichstraße 147
10117 Berlin
Telefon: 030/520026046
Fax: 030/520026046
eMail: thomaskunt@gmail.com